[Trastuzumab deruxtecan (breast cancer, after 1 prior therapy) - Addendum to Commission A22-80]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004354
German
Original Title:
Trastuzumab Deruxtecan (Mammakarzinom, nach 1 Vortherapie) Addendum zum Projekt A22-80 (Dossierbewertung)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a22-126.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a22-126_trastuzumab-deruxtecan_addendum-zum-projekt-a22-80_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Breast Neoplasms
- Trastuzumab
- Antineoplastic Agents, Immunological
- Immunoconjugates
Keywords
- Trastuzumab
- Breast Neoplasms
- Benefit Assessment
- NCT03529110
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.